Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country.
<h4>Objective</h4>This study aimed to evaluate the seroprevalence of anti-SARS-CoV-2 IgG and factors associated with the infection among PLWHIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso.<h4>Design</h4>A retrospective cross-sectional study of...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0286665 |
| _version_ | 1827923468565348352 |
|---|---|
| author | Odilon D Kaboré Armel Poda Cheick Ahmed Ouattara Fernand N Michodigni Abdoul-Aziz Belem Yacouba Sawadogo Jacques Zoungrana Lokman Galal Clément Z Meda Sylvain Godreuil Abdoul-Salam Ouédraogo |
| author_facet | Odilon D Kaboré Armel Poda Cheick Ahmed Ouattara Fernand N Michodigni Abdoul-Aziz Belem Yacouba Sawadogo Jacques Zoungrana Lokman Galal Clément Z Meda Sylvain Godreuil Abdoul-Salam Ouédraogo |
| author_sort | Odilon D Kaboré |
| collection | DOAJ |
| description | <h4>Objective</h4>This study aimed to evaluate the seroprevalence of anti-SARS-CoV-2 IgG and factors associated with the infection among PLWHIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso.<h4>Design</h4>A retrospective cross-sectional study of plasma samples collected from March 9, 2020, and March 8, 2021, at the outpatient HIV referral center, before the introduction of the SARS-CoV-2 vaccine in Burkina Faso.<h4>Methods</h4>Anti-SARS-CoV-2 IgG were detected in plasma using DS-ЕIA-ANTI-SARS-CoV-2-G (S) kit. Logistic regressions were used to compare SARS-CoV-2 specific immune responses between groups and within subgroups.<h4>Results and discussion</h4>A total of 419 plasma were subjected to serological diagnosis. None of the participants was vaccinated against COVID-19 during the period of sample collection, and 130 samples were positive for anti-SARS-CoV-2 IgG, giving a prevalence of 31.0% (95% CI 26.6-35.7). The median CD4 cell count was 661 cells/μL (IQR,422-928). Retailers had half the risk of being infected compared to housemaids with an OR of 0.49 (p = 0.028, 95% CI 0.26-0.91). Likewise, the risk of infection was 1.69 times higher in patients on integrase inhibitors compared to that of patients on non-nucleoside reverse transcriptase inhibitors (p = 0.020, 95% CI 1.09-2.63).<h4>Conclusion</h4>Our study reveals a high seroprevalence among PLWHIV to SARS-CoV-2 during the first year of the pandemic. In addition, PLWHIV on integrase inhibitors are 1.69 times more likely to be infected than PLWHIV on non-nucleoside inhibitors, and this observation remains an intriguing topic that still needs to be clarified. |
| first_indexed | 2024-03-13T04:59:19Z |
| format | Article |
| id | doaj.art-0bcaa101fe7f45449ce34552c3bdb6d9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-13T04:59:19Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0bcaa101fe7f45449ce34552c3bdb6d92023-06-17T05:31:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01186e028666510.1371/journal.pone.0286665Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country.Odilon D KaboréArmel PodaCheick Ahmed OuattaraFernand N MichodigniAbdoul-Aziz BelemYacouba SawadogoJacques ZoungranaLokman GalalClément Z MedaSylvain GodreuilAbdoul-Salam Ouédraogo<h4>Objective</h4>This study aimed to evaluate the seroprevalence of anti-SARS-CoV-2 IgG and factors associated with the infection among PLWHIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso.<h4>Design</h4>A retrospective cross-sectional study of plasma samples collected from March 9, 2020, and March 8, 2021, at the outpatient HIV referral center, before the introduction of the SARS-CoV-2 vaccine in Burkina Faso.<h4>Methods</h4>Anti-SARS-CoV-2 IgG were detected in plasma using DS-ЕIA-ANTI-SARS-CoV-2-G (S) kit. Logistic regressions were used to compare SARS-CoV-2 specific immune responses between groups and within subgroups.<h4>Results and discussion</h4>A total of 419 plasma were subjected to serological diagnosis. None of the participants was vaccinated against COVID-19 during the period of sample collection, and 130 samples were positive for anti-SARS-CoV-2 IgG, giving a prevalence of 31.0% (95% CI 26.6-35.7). The median CD4 cell count was 661 cells/μL (IQR,422-928). Retailers had half the risk of being infected compared to housemaids with an OR of 0.49 (p = 0.028, 95% CI 0.26-0.91). Likewise, the risk of infection was 1.69 times higher in patients on integrase inhibitors compared to that of patients on non-nucleoside reverse transcriptase inhibitors (p = 0.020, 95% CI 1.09-2.63).<h4>Conclusion</h4>Our study reveals a high seroprevalence among PLWHIV to SARS-CoV-2 during the first year of the pandemic. In addition, PLWHIV on integrase inhibitors are 1.69 times more likely to be infected than PLWHIV on non-nucleoside inhibitors, and this observation remains an intriguing topic that still needs to be clarified.https://doi.org/10.1371/journal.pone.0286665 |
| spellingShingle | Odilon D Kaboré Armel Poda Cheick Ahmed Ouattara Fernand N Michodigni Abdoul-Aziz Belem Yacouba Sawadogo Jacques Zoungrana Lokman Galal Clément Z Meda Sylvain Godreuil Abdoul-Salam Ouédraogo Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country. PLoS ONE |
| title | Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country. |
| title_full | Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country. |
| title_fullStr | Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country. |
| title_full_unstemmed | Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country. |
| title_short | Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country. |
| title_sort | seroprevalence of sars cov 2 igg and associated factors among people living with hiv over the first 12 months following the outbreak of covid 19 in burkina faso a sub saharan african country |
| url | https://doi.org/10.1371/journal.pone.0286665 |
| work_keys_str_mv | AT odilondkabore seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT armelpoda seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT cheickahmedouattara seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT fernandnmichodigni seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT abdoulazizbelem seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT yacoubasawadogo seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT jacqueszoungrana seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT lokmangalal seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT clementzmeda seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT sylvaingodreuil seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry AT abdoulsalamouedraogo seroprevalenceofsarscov2iggandassociatedfactorsamongpeoplelivingwithhivoverthefirst12monthsfollowingtheoutbreakofcovid19inburkinafasoasubsaharanafricancountry |